2-(3-chloro-2-oxo-propyl)-3a,4,7,7a-tetrahydro-isoindole-1,3-dione

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 异吲哚及其衍生物
• 英文名称: 2-(3-chloro-2-oxo-propyl)-3a,4,7,7a-tetrahydro-isoindole-1,3-dione
• 英文别名: 2-(3-Chloro-2-oxo-propyl)-3a,4,7,7a-tetrahydro-isoindole-1,3-dione；2-(3-chloro-2-oxopropyl)-3a,4,7,7a-tetrahydroisoindole-1,3-dione
• 化学式: C₁₁H₁₂ClNO₃
• 分子量: 241.674
• InChiKey: BILAIPCTORFKSP-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.7
• 重原子数：
  16
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.55
• 拓扑面积：
  54.4
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  2-(3-chloro-2-oxo-propyl)-3a,4,7,7a-tetrahydro-isoindole-1,3-dione 、 2-(1-methylethoxy)phenyl-1-piperazine 在 potassium carbonate 作用下， 以 DMF (N,N-dimethyl-formamide) 为溶剂， 以69%的产率得到2-(3-[4-(2-isopropoxy-phenyl)-piperazin-1-yl]-2-oxo-propyl)-3a,4,7,7a-tetrahydro-hydrochloride
  参考文献：
  名称：

  [EN] ARYLPIPERAZINE DERIVATIVES AS ADRENERGIC RECEPTOR ANTAGONISTS
  [FR] ANTAGONISTES DES RECEPTEURS ADRENERGIQUES

  摘要：

  公开号：

  WO2005118537A3
• 作为产物：
  描述：

  2-(3-chloro-2-hydroxy-propyl)-3a,4,7,7a-tetrahydro-isoindole-1,3-dione 在 pyridinium chlorochromate 作用下， 以 二氯甲烷 为溶剂， 以75%的产率得到2-(3-chloro-2-oxo-propyl)-3a,4,7,7a-tetrahydro-isoindole-1,3-dione
  参考文献：
  名称：

  [EN] ARYLPIPERAZINE DERIVATIVES AS ADRENERGIC RECEPTOR ANTAGONISTS
  [FR] ANTAGONISTES DES RECEPTEURS ADRENERGIQUES

  摘要：

  公开号：

  WO2005118537A3

文献信息

• ARYLPIPERAZINE DERIVATIVES AS ADRENERGIC RECEPTOR ANTAGONISTS
  申请人：Salman Mohammad

  公开号：US20090312344A1

  公开（公告）日：2009-12-17

  The present invention relates to α 1 , and/or α 1d adrenergic receptor antagonists, which can function as α 1a and/or α 1d adrenergic receptor antagonist and can be used for the treatment of a disease or disorder mediated through α 1a and/or an adrenergic receptor. Compounds disclosed herein can be used for the treatment of benign prostatic hyperplasia (BPH) and the related symptoms thereof. Further, compounds disclosed herein can be used for the treatment of lower urinary tract symptoms associated with or without BPH. Also provided are processes for preparing such compounds, pharmaceutical compositions thereof, and the methods of treating BPH or related symptoms thereof.

  本发明涉及α1和/或α1肾上腺素受体拮抗剂，其可以作为α1a和/或α1d肾上腺素受体拮抗剂，可用于治疗通过α1a和/或肾上腺素受体介导的疾病或紊乱。本文所披露的化合物可用于治疗良性前列腺增生症（BPH）及其相关症状。此外，本文所披露的化合物可用于治疗与或不伴随BPH的下尿路症状。还提供制备此类化合物的方法，其制药组合物以及治疗BPH或其相关症状的方法。
• ARYLPIPERAZINE DERIVATIVES USEFUL AS ADRENERGIC RECEPTOR ANTAGONISTS
  申请人：Ranbaxy Laboratories Limited

  公开号：EP1758583A2

  公开（公告）日：2007-03-07
• [EN] ADRENERGIC RECEPTOR ANTAGONISTS<br/>[FR] ANTAGONISTES DES RECEPTEURS ADRENERGIQUES
  申请人：RANBAXY LAB LTD

  公开号：WO2005118537A2

  公开（公告）日：2005-12-15

  The present invention relates to α1a and/or α1d adrenergic receptor antagonists of formula (I), which can function as α1a and/or α1d adrenergic receptor antagonist and can be used for the treatment of a disease or disorder mediated through α1a and/or α1d adrenergic receptor. Compounds disclosed herein can be used for the treatment of benign prostatic hyperplasia (BPH) and the related symptoms thereof. Further, compounds disclosed herein can be used for the treatment of lower urinary tract symptoms associated with or without BPH. Also provided are processes for preparing such compounds, pharmaceutical compositions thereof, and the methods of treating BPH or related symptoms thereof.
• [EN] ARYLPIPERAZINE DERIVATIVES AS ADRENERGIC RECEPTOR ANTAGONISTS<br/>[FR] ANTAGONISTES DES RECEPTEURS ADRENERGIQUES
  申请人：RANBAXY LAB LTD

  公开号：WO2005118537A3

  公开（公告）日：2006-06-01